Introduction
============

Diabetes mellitus is one of the most prevalent noncommunicable chronic diseases around the world which is spreading rapidly in epidemic proportions ([@b1-ijph-39-082]). There are reports that patients with diabetes are faced with increasing oxidative stress, elevated production of oxygen free radicals (OFRs) and insufficient antioxidant defense mechanism ([@b2-ijph-39-082]--[@b4-ijph-39-082]). On the other hand, hyperlipidemia is one of the causative factors of increased lipid peroxidation due to metabolic imbalances in diabetes ([@b2-ijph-39-082]). Different studies have demonstrated that the lipid composition of atheroma in atherosclerotic plaques is similar to that of blood lipids ([@b5-ijph-39-082]) and a close relationship exists between dietary lipids and atheromatous plaques in coronary artery disease ([@b4-ijph-39-082]). In addition, the type of dietary lipids has been more important than the total consumed lipids ([@b5-ijph-39-082]). Therefore, consumption of omega-3 fatty acids present in deep sea and cold water fish in wild vegetables with dark green color leaves or in animals grazing freely in the wild have been recommended ([@b3-ijph-39-082], [@b6-ijph-39-082]--[@b8-ijph-39-082]). Omega-3 fatty acids (DHA, EPA) are essential for cell membrane structure and function ([@b9-ijph-39-082]).

Some studies have reported the dual effects of antioxidative defense mechanisms in diabetes where increased or decreased antioxidant levels are observed ([@b10-ijph-39-082]). Conversely, unpredictable effects of materials containing omega-3 predisposing the subjects to lipid peroxidation in aerobic conditions have been reported too ([@b11-ijph-39-082]). These instances normally occur in aerobic conditions in the absence of antioxidants ([@b9-ijph-39-082]). Recent studies have shown that polyunsaturated fatty acids can act as an antioxidant in-vivo ([@b12-ijph-39-082], [@b13-ijph-39-082]) if they are consumed with adequate amounts of vitamin E to act as an scavenger for reactive oxygen species as do omega 3 and 6 in similar in-vivo conditions ([@b14-ijph-39-082]).

Therefore, this study was undertaken in patients with diabetes type II with a BMI of ≥ 25--30 to evaluate the effects of pure eicosapentaenoic acid (EPA) with and without vitamin E on lipid peroxidation indices, enzymatic antioxidant activity, and total serum antioxidant capacity to find an appropriate approach for dietary modifications and prevent related complications in these patients.

Materials and Methods
=====================

Study population
----------------

The study population consisted of 136 patients with type II diabetes mellitus (an individual being treated by oral hypoglycemic agents or having a fasting plasma glucose concentration \>7.0 mmol/L) ([@b15-ijph-39-082]).

The inclusion criteria included being 35--50 yr old, male or female, with a BMI ≥ 25--30, having been diagnosed with diabetes for 2--15 yr, no recent (past year) digestive, renal, microalbuminuria ([@b16-ijph-39-082]), hepatic, cardiovascular, thyroid or respiratory diseases or a diagnosed cancer. Additionally, being non-alcoholic, non-smoker, with no history of drug abuse, ongoing pregnancy or breast-feeding were the other criteria for inclusion in the study.

Study design
------------

In this placebo-controlled, double blinded study with parallel designs, subjects were randomly assigned to one of four groups and for duration of diagnosed diabetes, after signing an informed consent form. The individuals filled a demographic form and reported a 24 h dietary recall, as they did two more times during the study. The four groups included: (P)= The placebo or the group receiving four grams of corn oil,(EPA)= The EPA group receiving two grams of EPA supplement + placebo(E)= The vitamin E group receiving 400 *IU* of vitamin E supplement + placebo(EPA+E)= The EPA plus vitamin E group receiving two grams of EPA supplement + 400 *IU* of vitamin E

The individuals were told to take the supplements postprandially (after lunch) without drinking hot fluids. The regimen continued for 12 wk, while they took their antidiabetic agents as before. The subjects were also recommended not to change their diet or their physical activity until the end of the study.

The subjects' weight, BMI and blood pressure were measured and they were referred to laboratory at the beginning and at end of the 12^th^ wk.

All the subjects were closely followed up every two weeks for weight, BP and BMI measurements and the way they were taking the supplement compliance, their diet and physical activity and by phone for making sure they were following the recommendations.

For blood pressure measurements, the individuals' right arm systolic pressure was measured in sitting position after five minutes of rest. The mean arterial pressure (MAP) and plus pressure (PP) were measured by the following formula ([@b17-ijph-39-082]): $$\begin{array}{ll}
{\text{MAP} = (2\text{DBP} + \text{SBP})/3} & {\text{PP} = {\text{SBP} - \text{DBP}}} \\
\end{array}$$The patients' weight and height were measured by a Seca height and weight measuring scale (Seca 725 gmbh & co. kg., Germany) and BMI was calculated by using weight/hight^2^m formula.

The Ethics Committee of Tehran University of Medical Sciences approved the study proposal. An individual outside the study was asked to help allocate the medications to the groups.

Supplement Characteristics
--------------------------

Plus EPA 500 mg pearls containing pure EPA (95%) from Minami, Nutrition, Belgium and Vitamin E pearls containing 400 *IU* of α-Tocopherol from (Dana Pharmaceutical Company, Tabriz, Iran) were used.

Blood collection
----------------

Venous blood samples were drawn in empty and in EDTA vacuum tubes after an overnight fast. Plasma and erythrocytes (RBC) were separated by centrifugation at 3000 rpm for 10 min at room temperature. RBCs were washed three times with 0.9% NaCl solution, and then hemolyzed with four volumes of cold distilled water. Plasma samples and erythrocyte lysates were stored at −70° C until assayed. Samples were protected from the natural light.

Serum Total Antioxidant Capacity, Enzymatic Antioxidants, Malondialdehyde and Protein Carbonyl
----------------------------------------------------------------------------------------------

Fasting serum Total Antioxidant Capacity (TAC) was measured at baseline and at the end of the intervention by 2,2′-Azino-bis(3-Ethylbenzthiazoline-6-Sulfonic Acid (ABTS) ([@b18-ijph-39-082]). Erythrocyte activity of Glutathione Peroxidase (G-PX) and Glutathione Reductase (G-RD) were assessed in the hemolysates by RANDOX kit (RANDOX Laboratories Ltd, United Kingdom) ([@b19-ijph-39-082]). The coefficient of variability between assays was 4%. The activity of SOD was measured at 500 nm by testing the inhibition degree of tetrazolium salt oxidation reaction (RANDOX kit) ([@b20-ijph-39-082]). The coefficient of variability between assays was 4.2%.

Fasting serum Catalase (CAT) activity was measured according to Hego Aebi's method ([@b21-ijph-39-082]) and serum MDA activities were determined using the thiobarbituric acid method ([@b22-ijph-39-082]).

Protein oxidation was determined by measuring the carbonyl groups on the amino acids of plasma proteins. With this method, the carbonyl groups react with 2,4-dinitrophenylhydrazine to form 2, 4-dinitrophenylhydrazone derivatives, which can be measured spectrophotometrically ([@b23-ijph-39-082]).

Samples obtained at baseline and at the end of the intervention were measured in a single assay to minimize inter-assay variations.

Dietary survey
--------------

The subjects' food intake was assessed by two dietitians using an open-ended, interview-administered diet history. Subjects were asked on their daily diet over a week period (24 h recall report, 3 times: Saturday, Monday and Thursday). Energy and nutrient intakes were calculated by using the Food Processor (version 2, Esha Research, USA) software.

Statistical analysis
--------------------

The data were analyzed using SPSS (version 16.0 for Windows, Polar Engineering and Consulting, USA) by general linear models to assess the effects of EPA, E, or EPA+E relative to the placebo. All variables were tested for normality by using histograms and Kolmogorov-Smirnov statistics. If the data distribution was not normal, either before or after the intervention, they were log transformed for statistical analysis.

Significance levels were adjusted for multiple comparisons by using Bonferroni method. Differences between the four groups were considered significant when *P*\< 0.05 (after Bonferroni adjustment). All values were reported as means±SEMs except for the demographic data of the patients at baseline, which are reported as means±SDs or as percentage (%).

Results
=======

Study population
----------------

At the beginning of the study, 136 patients were recruited and 127 patients finished the study successfully (without any changes or fluctuations in taking the supplements, physical activity or diet). Two subjects withdrew because of digestive intolerance to the supplements, two for unplanned journeys, two for incompliance to the program, one for appendectomy, one for immigration while one subject withdrew because he could not attend the center for blood measurement in the final stage. Baseline characteristics of the four groups confirmed that they had been well-matched for the entry criteria ([Table 1](#t1-ijph-39-082){ref-type="table"} and [2](#t2-ijph-39-082){ref-type="table"}). There were no significant differences between the groups in either the type or number of oral hypoglycemic medications. The subjects also took oral hypoglycemic agents in the form of biguanides with sulfonylureas (76%), sulfonylureas (16%) or biguanides agents (8%).

Energy and macronutrient intakes
--------------------------------

Evidence of adherence to the diets was confirmed by analyzing the diet recall records and supplement counts.

Analysis of diet records indicated that total energy and major macronutrient and micronutrient intakes were not significantly different between the groups at baseline ([Table 2](#t2-ijph-39-082){ref-type="table"}) and did not change significantly in any of the groups during the intervention. Antidiabetic agents were unchanged during the intervention in all groups too.

Serum Antioxidants
------------------

There were no significant differences between the groups regarding fasting serum total antioxidant capacity, enzymatic antioxidants, malondialdehyde and protein carbonyl at baseline ([Table 3](#t3-ijph-39-082){ref-type="table"}). Changes in fasting serum total antioxidant capacity, enzymatic antioxidants, malondialdehyde and protein carbonyl are shown in ([Table 3](#t3-ijph-39-082){ref-type="table"}).

Fasting serum TAC was significantly higher at the end of the intervention than the baseline in the EPA+E and E groups (10.7%, *P*\< 0.05 and 7.5%, *P*\< 0.05; respectively).

Fasting serum SOD was significantly higher at the end of the intervention, compared to baseline values, in EPA (7.3%, *P*\< 0.05), EPA+E and E groups (5.7% and 4.8%; NS) but it decreased in the placebo group (3%, NS).

A significant increase was seen in catalase activity in EPA+E groups (7.5%, *P*\< 0.04) ([Table 3](#t3-ijph-39-082){ref-type="table"}). Serum G-PX activity had a significant increase in EPA (5.1%, *P\<* 0.05), and non-significant increases were found in EPA+E and E groups (2% and 4.2%, respectively), while the placebo group underwent a non-significant decrease (NS).

Serum G-RD activity underwent a significant increase in EPA (by 8.4% *P*\< 0.05).

Fasting serum MDA decreased in all groups except placebo, but it was statistically significant in EPA (12.5%, *P*\< 0.05) and E groups (13%, *P*\< 0.05). Fasting serum protein carbonyl decreased in E, EPA and EPA+E groups (15.3%, *P*\< 0.05; 7.6%, *P* \< 0.05 and 6%, NS).

After adjustment for baseline values, age, sex, BMI and duration of diagnosed diabetes, dietary ingredients, all enzymetic antioxidant, TAC and MDA did not have any significant differences among all groups, but fasting serum protein carbonyl in EPA+E and E groups had a significant decrease relative to the placebo (30.7%, *P*\< 0.05; 15.3%, *P*\< 0.05; respectively) ([Table 3](#t3-ijph-39-082){ref-type="table"}).

Discussion
==========

In this study, purified EPA +E had a significant effect on TAC and CAT activities in patients with diabetes type II. EPA alone had significant effects on serum enzymatic antioxidants as measured by SOD, G-PX and G-RD, except CAT and peroxidation indices as measured by MDA and protein carbonyl.

Although worries about the consumption of n3-PUFA and increased lipid peroxidation have lingered about for some time, but in the present study the index for lipid peroxidation (MDA) was not only decreased about 12.5% (*P*\< 0.05) but the protein peroxidation index (protein carbonyl) was also decreased about 7.6% (*P*\< 0.05) in diabetic patients receiving two grams of daily EPA for three months. However, in patients on EPA+E, lipid and protein peroxidation indices underwent statistically insignificant decreases MDA 4.7% and protein carbonyl 6%. These worries have also been reported on the use of n3-PUFA by Mori et al. ([@b24-ijph-39-082], [@b25-ijph-39-082]) and Trevor et al. ([@b26-ijph-39-082], [@b27-ijph-39-082]). They found that in vivo consumption of fish, providing four grams of omega-3, in diabetes type II patients did not confirm the theorem of increased lipid and protein peroxidations after n3-PUFA consumption and instead it decreased the oxidations shown by decreases in urinary F2-isoprostan ([@b27-ijph-39-082]).

By this finding Mori et al had once again proven their previous studies carried out in 2000 in which consumption of EPA and pure DHA in comparison with olive oil in overweight people with hyperlipidemia had resulted in a 27% and 26% decrease in urinary F2-isoprostan ([@b28-ijph-39-082], [@b29-ijph-39-082]). They believed that decrease in oxidative stress had been due to the anti-inflammatory effects of omega-3 fatty acids executed by reduction of free radical formation in white blood cells ([@b27-ijph-39-082]).

On the other hand, studies such as the one by Ramirez have demonstrated that MDA levels decrease in old people upon omega-3 intake and LDL susceptibility to oxidation decreases in invitro environment containing metallic ions ([@b30-ijph-39-082]). Carpentier et al. also depicted this decrease in oxidative stress by administrating four grams of EPA or DHA in overweight subjects with hyperlipidemia ([@b31-ijph-39-082]) as did Tanaka in Japan by administering 2.7 gr of pure EPA in overweight 27--74 yr old subjects with non-alcoholic hepatic steatorea and showed decreases in thioreduction as an index for oxidative stress in hepatic cells. Regarding his remarkable results, Tanaka suggested addition of pure EPA to statins ([@b13-ijph-39-082]) and in his next Japan EPA Lipid Intervention Study (JELIS) he observed remarkable decreases in oxidative stress indices upon addition of 1.8 gr of pure EPA to statins in CHD patients with hyperlipidemia ([@b32-ijph-39-082]). However, Sumida *et al* observed the decreasing effects of three grams of EPA administration on serum ferritin and thioreduction, two hepatic oxidative stress markers, separately in 2000 and in 2003 ([@b33-ijph-39-082], [@b34-ijph-39-082]). They also observed a remarkable reduction in hepatic MDA concentration and 4-Hydroxyneonal content following an increase in the expression of SOD genes containing Cu, Mn and Zn ([@b33-ijph-39-082], [@b34-ijph-39-082]). Similarly, we demonstrated SOD enzyme activity in three groups of subjects taking EPA, EPA+E and E, respectively 7.3%, 5.7% and 4.7%, with statistically significant results in the group taking EPA (*P*\< 0.05*)*. Sumida reported the reduction of triglyceride proportion to hepatic free fatty acid concentration as an effective factor in MDA reduction, contrary to their belief regarding the useful antioxidative effects of EPA ([@b33-ijph-39-082], [@b34-ijph-39-082]). Moreover, Tanaka et al. reported that EPA not only exerted its anti-inflammatory effects through decreased excavation of fatty acids by hepatocytes, it but also eliminated oxidative stress produced by arachidonic acid. They also showed that EPA reduced the nuclear factor \[Kappa\]-B and metamorphosis of its subunits. EPA also declined damage to hepatocytes by improving their membrane fluidity ([@b13-ijph-39-082]).

Although increases in the consumption of oily fish caused a source of concern, where increased LDL oxidation might aggravate atherosclerosis, but numerous studies have shown that the fatty acids in LDL, which originate from oil in food regimens leave LDL susceptible to oxidative changes. Therefore, it is expected that n3-PUFA consumption increase LDL oxidation ([@b11-ijph-39-082]) but in the present study the concentration of all serum enzymatic antioxidants were remarkably increased in the EPA group, especially SOD, G-PX and GRD (Respectively, 7.3%, 5.1% and 8.4%, *P*\< 0.05). Although Higgins et al showed that serum anti-oxidant enzymes undergo no changes by administering different doses of fish oil in healthy subjects aged 19--63 yr over a period of 16 wk but they had used EPA doses of 0.3, 0.6 and 0.9 grams which were smaller than the doses used in the present study ([@b11-ijph-39-082]).

In short-term supplementation with n3-PUFA, LDL and other membranous lipids undergo oxidation, which requires double-band fatty acids smaller than n3-PUFA. Brude et al. believed reduced oxidation rate following n3-PUFA consumption were due to tight packing of EPA and DHA in lipid membrane complex which provides fewer double bonds for interaction with free radicals ([@b29-ijph-39-082]).

Another hypothesis provided by Brude relies on the fact that n3-PUFAs internally regulate anti-oxidant systems ([@b29-ijph-39-082]). Upon introduction of this hypothesis, it was demonstrated that plasma and platelet concentrations of x-carotene increased after n3-PUFA supplementation ([@b11-ijph-39-082]). Therefore, this adaptive effect was introduced to better justify the process when enhanced lipid oxidability is more often seen in short-term rather than long-term supplementation. Increased LDL oxidations have been reported in 3, 5 and 6 wk supplementations in contrast to 5, 6, and 8 up to 16 wk supplementations resulting in a decrease in LDL oxidation ([@b11-ijph-39-082]). In the present 12 wk study, MDA and protein carbonyl underwent significant decreases upon supplementation with two grams of EPA. Additionally, numerous studies on the propriety of applied doses of n3-PUFA have shown LDL oxidation will not occur in doses smaller than 2.5 gr/day but unwanted effects of n3-PUFA on lipid oxidation, especially LDL, will be seen in doses greater than or equal 2.5 gr/day ([@b11-ijph-39-082]).

In conclusion, it seems that EPA by itself has a statistically significant effect on serum total antioxidant capacity, enzymatic antioxidants and peroxidation indices in diabetic patients compared to EPA+E or vit E alone. Larger studies may be needed to confirm the results of the study.
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###### 

Characteristics of participants in four groups at baseline*[^1^](#tfn1-ijph-39-082){ref-type="table-fn"}*

  **Treatment group**                  **EPA+E (n=34)**   **EPA (n=34)**   **E (n=32)**   ***P* (n=36)**
  ------------------------------------ ------------------ ---------------- -------------- ----------------
  Age (Y)                              45 ± 4.3           44 ± 5.0         44± 4.4        45± 4.1
  Gender (M/F) (%)                     67/32              58/41            53/46          63/36
  Weight (kg)                          72.2± 8.1          74.3± 8.4        72.4± 9.6      70.5± 8.3
  BMI (kg/m^2^)                        27.8± 2.4          27.9± 1.7        27.8± 1.6      27.8±1.6
  Duration of diagnosed diabetes (y)   7.5± 4.2           7.4 ± 3.9        7.1± 3.5       8.3 ± 3.9
  Mean Blood Pressure (mmHg)           90± 6.1            89± 6.3          86± 6.2        90±7.1
  Pulse pressure (mmHg)                41±10              41± 7            42± 10         48±12

X-bar± SD or %. There were no significant differences between the four groups at baseline (by UNIANOVA). Chi-square test was used to detect differences in gender profile between the groups. \[EPA= eicosapentaenoic acid; E= Vitamin E\].

###### 

Total energy and macro and micronutrient intakes at baseline and postintervention after 3 months in four groups*[^1^](#tfn2-ijph-39-082){ref-type="table-fn"}*

  **Treatment group**                               **EPA+E (n=34)**   **E (n=32)**   **EPA (n=34)**   ***P* (n=36)**
  ------------------------------ ------------------ ------------------ -------------- ---------------- ----------------
  Total energy intake (kcal/d)   Baseline           1656 ± 372         1764 ± 403     1616±336         1793±395
                                 Postintervention   1635 ± 292         1742 ± 428     1653±373         1838± 409
  Total fat (g/d)                Baseline           64± 15             70± 18         63± 19           70±18
                                 Postintervention   68± 20             70± 21         62±18            68±21
  Saturated fat (g/d)            Baseline           21±7               22 ±9          20±7             22±9
                                 Postintervention   21±6               23 ±8          21±6             22± 7
  Monounsaturated fat (g/d)      Baseline           19±5               21±5           18± 6            21±5
                                 Postintervention   20±6               21±7           18±5             21± 7
  Polyunsaturated fat (g/d)      Baseline           19±5               23±8           19± 8            23±8
                                 Postintervention   21±9               21±7           19±9             20±8
  Cholesterol (g/d)              Baseline           206±106            216±123        195±113          200±112
                                 Postintervention   232±111            213±124        184±78           192±105
  Protein (g/d)                  Baseline           60±15              60±18          56±13            62±18
                                 Postintervention   64±13              66±19          56±11            64±17
  Carbohydrate (g/d)             Baseline           220±66             241± 73        215± 47          239±67
                                 Postintervention   229±55             239±64         218±50           243±60
  Fiber (g/d)                    Baseline           15± 5              17±6           16±6             17±6
                                 Postintervention   17±6               17±7           15±5             18±6
  Vit A (mcg/d)                  Baseline           1073± 1365         1165±1364      844 ±587         890±637
                                 Postintervention   981± 652           1100 ± 679     809± 545         974±624
  Vit E (mg/d)                   Baseline           13±5               17 ± 9         14± 6            17 ± 9
                                 Postintervention   15±8               17± 8          14± 9            16 ± 9
  Vit C (mg/d)                   Baseline           99±58              86± 66         58± 38           82± 57
                                 Postintervention   97±53              84 ±68         68±51            83± 64
  Selenium (mcg/d)               Baseline           121±43             128± 46        120± 41          131±42
                                 Postintervention   132±34             125±40         114± 43          123±34
  Fe (mg/d)                      Baseline           11±2               11±2           10 ±2            12±3
                                 Postintervention   11±2               10±2           10 ±2            11±3
  Zinc (mg/d)                    Baseline           8±3                8±2            8±2              8±2
                                 Postintervention   9±2                9± 2           8±2              8±2
  Mg (mg/d)                      Baseline           123±31             124 ±36        118± 32          124±41
                                 Postintervention   111±27             122±36         117±32           122±31

X-bar±SD. Baseline and Postintervention measures were compared by paired t-test (within groups) and between groups by UNIANOVA. There were no significant differences between the groups in any of the dietary nutrients at baseline and no significant changes during the intervention. \[EPA= eicosapentaenoic acid; E = Vitamin E\].

###### 

Fasting serum TAC, SOD, CAT, G-PX, G-RD, MDA and Pro-Carbonyl at baseline and Postintervention in four groups*[^1^](#tfn3-ijph-39-082){ref-type="table-fn"}*

  **Treatment group**              **EPA+E (n=34)**                                         **EPA (n=34)**                                             **E (n=32)**                                            ***P* (n=36)**   **Treatment effect (p)*[^2^](#tfn5-ijph-39-082){ref-type="table-fn"}***                                                                        
  -------------------------------- -------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------- ---------------- ------------------------------------------------------------------------- ------------- ------------------------------------------------------ -------------------------------------------------------
  TAC (mg/dl)                      Baseline                                                 2.8 ± 0.4                                                  3.0 ± 0.3                                               2.8 ± 0.4        2.9 ± 1.2                                                                 +0.2 ± 0.3    +0.3 ± 0.3                                             +0.0 ± 0.3
  Postintervention                 3.1± 0.3[\*](#tfn4-ijph-39-082){ref-type="table-fn"}     3.1± 0.3                                                   3.1 ± 0.3[\*](#tfn4-ijph-39-082){ref-type="table-fn"}   2.9 ± 0.3                                                                                                                                                       
  SOD (U/gHb)                      Baseline                                                 1068.9±350.4                                               1061.7±241.1                                            990.1±243.1      1071.4±250.9                                                              +134.7±71.7   +4.5±78.3                                              +20.7±72.9
  Postintervention                 1130.9± 257.8                                            1139.5±238.1[\*](#tfn4-ijph-39-082){ref-type="table-fn"}   1038.0±237.3                                            1039.1±228.6                                                                                                                                                    
  CAT (U/gHb)                      Baseline                                                 202.1±34.6                                                 205.0± 30.9                                             203.4± 32.0      201.8± 39.2                                                               +23.6±14.9    +6.3±16.2                                              +5.0 ±15.1
  Postintervention                 217.4±48.3[\*](#tfn4-ijph-39-082){ref-type="table-fn"}   221.7±58.8                                                 214.7± 53.8                                             200.5± 48.0                                                                                                                                                     
  G-PX (U/gHb)                     Baseline                                                 43.8± 6.7                                                  40.9±5.8                                                44.5 ± 8.1       42.5± 5.7                                                                 +0.6± 1.9     +1.4 ± 2.0                                             +2.6 ± 1.9
  Postintervention                 44.8± 6.2                                                43.0±8.0[\*](#tfn4-ijph-39-082){ref-type="table-fn"}       46.4 ± 7.1                                              42.3± 4.6                                                                                                                                                       
  G-RD (U/gHb)                     Baseline                                                 5.4 ±1.8                                                   4.4 ±1.4                                                4.4 ±2.3         4.6± 1.4                                                                  −0.1± 0.5     +0.9± 0.5                                              +0.3± 0.5
  Postintervention                 5.7±1.7                                                  4.8 ±1.7[\*](#tfn4-ijph-39-082){ref-type="table-fn"}       5.0 ± 2.2                                               4.6 ± 1.4                                                                                                                                                       
  MDA (ng/ml)                      Baseline                                                 2.1± 0.4                                                   2.4 ± 0.6                                               2.3 ± 0.6        2.3± 0.6                                                                  −0.2± 0.1     −0.3± 0.1                                              −0.3± 0.1
  Postintervention                 1.9 ± 0.5                                                2.1 ±0.3[\*](#tfn4-ijph-39-082){ref-type="table-fn"}       2.0 ± 0.6[\*](#tfn4-ijph-39-082){ref-type="table-fn"}   2.1± 0.4                                                                                                                                                        
  Pro-Carbonyl (nmol/mg protein)   Baseline                                                 1.0 ± 0.3                                                  1.3 ± 0.3                                               1.3 ± 0.3        1.3± 0.3                                                                  −0.2± 0.0     −0.3± 0.1[‡](#tfn6-ijph-39-082){ref-type="table-fn"}   −0.2 ± 0.0[‡](#tfn6-ijph-39-082){ref-type="table-fn"}
  Postintervention                 0.9 ± 0.2                                                1.2 ±0.2[\*](#tfn4-ijph-39-082){ref-type="table-fn"}       1.2 ± 0.2[\*](#tfn4-ijph-39-082){ref-type="table-fn"}   1.2± 0.5                                                                                                                                                        

x-bar ± SD. There were no significant differences between the four groups at baseline (by UNIANOVA).

Significantly different from before and after treatment (by paired t-test) within groups: *P*\< 0.01.

*x̄* ± SEM, A general linear model (ANCOVA) was used to assess treatment effects on Postintervention values adjustment for age, sex, BMI, duration of diagnosed diabetes and baseline valuse.

Significantly changes for each of the three treatment groups relative to the corn oil group. \[EPA= eicosapentaenoic acid; E= Vitamin E; TAC= *Total Capacity of Antioxidant*; CAT= *Catalase*; SOD= *Superoxide Dismutase*; G-PX*= Glutathione Peroxidase;* G-RD= *Glutathione Reductase;* MDA*= Malondialdehyde*; Pro-Carbonyl = *Protein Carbonyl*\].
